Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 17, 2009, Pages 7022-7027

  Wu, Min ^a   Jung, Lina ^a   Cooper, Adrian B ^a   Fleet, Christina ^a   Chen, Lihao ^a   Breault, Lyne ^a   Clark, Kimberly ^a   Cai, Zuhua ^a   Vincent, Sylvie ^a   Bottega, Steve ^a   Shen, Qiong ^a   Richardson, Andrea ^b   Bosenburg, Marcus ^c   Naber, Stephen P ^d   DePinho, Ronald A ^e,f   Kuperwasser, Charlotte ^g   Robinson, Murray O ^a  

^a AVEO ONCOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer model; Human in mouse; Tissue reconstitution

Indexed keywords

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER MODEL; CANCER PATIENT; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; TRANSGENIC MOUSE; ANIMAL; APOPTOSIS; BREAST TUMOR; CANCER INVASION; CELL TRANSFORMATION; DISEASE COURSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIMIAN VIRUS 40;

MUS;

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RAS PROTEIN; TELOMERASE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM INVASIVENESS; RAS PROTEINS; RECEPTOR, ERBB-2; RNA INTERFERENCE; SIMIAN VIRUS 40; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66349136558     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811785106     Document Type: Article

References (23)

1. Campbell IG, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678-7681.
2. Coles C, et al. (1992) p53 mutations in breast cancer. Cancer Res 52:5291-5298.
3. Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98:415-418.
4. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
5. Finn RS, Slamon DJ (2003) Monoclonal antibody therapy for breast cancer: Herceptin. Cancer Chemother Biol Response Modif 21:223-233.
6. Truong K, et al. (1999) Evidence for in vitro selection during cell culturing of breast cancer: Detection by flow and image cytometry. Cancer Genet Cytogenet 114:154 -155.
7. Sharpless NE, Depinho RA (2006) The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741-754.
8. Kuperwasser C, et al. (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101:4966-4971.
9. Parmar H, et al. (2002) A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts. Endocrinology 143:4886-4896.
10. Bacus SS, et al. (1992) HER-2/neu oncogene expression, DNA ploidy and proliferation index in breast cancer. Anal Quant Cytol Histol 14:433-445.
11. Miyakis S, Sourvinos G, Spandidos DA (1998) Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun 251:609-612.
12. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
13. Mé nard S, et al. (2001) HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 12:S15-S19.
14. Tsuda H, Hirohashi S (1998) Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions. Pathol Int 48:518-525.
15. Guy CT, Cardiff RD, Muller WJ (1996) Activated neu induces rapid tumor progression. J Biol Chem 271:7673-7678.
16. Zhao JJ, et al. (2003) Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3:483-495.
17. Liu H, et al. (2008) Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 39:167-174.
18. Elenbaas B, et al. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15:50-65.
19. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO (1999) Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13:2388-2399.
20. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
21. Lin J, et al. (2007) AV-412, a potent EGFR/HER2 TK inhibitor causes tumor regression in novel genetically engineered EGFRL858R and EGFRL858R&T790M lung tumor models. In American Association for Cancer Research Annual Meeting: Proceedings (American Association for Cancer Research, Philadelphia), abstr 4008.
22. Mohsin SK, et al. (2005) Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468.
23. Napoli M (2001) Overdiagnosis and overtreatment. Am J Nurs 101:11.